⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent high grade fallopian tube serous adenocarcinoma

Every month we try and update this database with for recurrent high grade fallopian tube serous adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerNCT02898207
Metastatic High...
Metastatic Mali...
Metastatic Prim...
Metastatic Trip...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Breas...
Recurrent High ...
Recurrent High ...
Recurrent Prima...
Recurrent Tripl...
Refractory Fall...
Refractory Ovar...
Refractory Prim...
Refractory Trip...
Unresectable Hi...
Unresectable Ma...
Unresectable Pr...
Olaparib
Onalespib
18 Years - National Cancer Institute (NCI)
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsNCT05114421
High Grade Fall...
High Grade Ovar...
Peritoneal High...
Recurrent High ...
Recurrent High ...
Recurrent Prima...
Lenvatinib
Pembrolizumab
18 Years - M.D. Anderson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: